Dr. Richter on Pomalidomide as Sickle Cell Disease Treatment

Joshua Richter, MD
Published: Wednesday, May 14, 2014



Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses using the FDA-approved multiple myeloma drug pomalidomide to treat patients with sickle cell disease.

Richter says sickle cell disease is difficult to manage as there are few therapies available. Hydroxyurea, which increases the levels of fetal hemoglobin to help prevent sickling, is commonly used to treat sickle cell disease. However, Richter says this therapy can lower blood counts and cause other issues.

Pomalidomide, which was approved by the FDA in February 2013 as treatment for relapsed and refractory multiple myeloma, increases the levels of fetal hemoglobin without some of the toxicities associated with hydroxyurea, Richter says. There is currently a phase I study examining the efficacy of pomalidomide in patients with sickle cell disease.

Though further studies are needed, Richter says researchers may be on to a new way of treating patients with sickle cell disease.



Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses using the FDA-approved multiple myeloma drug pomalidomide to treat patients with sickle cell disease.

Richter says sickle cell disease is difficult to manage as there are few therapies available. Hydroxyurea, which increases the levels of fetal hemoglobin to help prevent sickling, is commonly used to treat sickle cell disease. However, Richter says this therapy can lower blood counts and cause other issues.

Pomalidomide, which was approved by the FDA in February 2013 as treatment for relapsed and refractory multiple myeloma, increases the levels of fetal hemoglobin without some of the toxicities associated with hydroxyurea, Richter says. There is currently a phase I study examining the efficacy of pomalidomide in patients with sickle cell disease.

Though further studies are needed, Richter says researchers may be on to a new way of treating patients with sickle cell disease.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Oncology Briefings™: Updates in Rare Hematology: Advancing Care and Improving Outcomes for Patients with Aplastic AnemiaAug 31, 20181.0
Publication Bottom Border
Border Publication
x